![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, February 07, 2017 2:31:56 PM
Viaderma Inc (OTCMKTS:VDRM) is a penny stock that has started to engage some focus among traders and investors as prices get a little traction in bounce mode. The company caught a bit of renewed momentum last week as a consequence of its announcement of a first order from its product manufacturer for a rollout of its FDA-registered drug, Viabecline, a topical antibiotic.
According to the release, the Company expects sales for 2017 to be about 500,000 units and has completed financing to produce the orders. “The rollout in California is expected to start with approximately 10,000 units being distributed online through an online network of affiliates. The products are anticipated to sell for approximately $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers.”
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM